Abstract 19214: Non Invasive Assessment of Myocardial Fibrosis in Human Atrial Fibrillation
Background and objective: Atrial fibrosis is common in patients with atrial fibrillation (AF) and causes abnormal conduction through the atria creating a substrate for AF. Therefore, the early detection of myocardial fibrosis could be relevant for the improvement in the diagnosis of this pathology. On the other hand, it has been demonstrated that procollagen type I C-terminal propeptide (PICP) is a good biomarker of collagen accumulation in the myocardium of hypertensive patients. Therefore, this study has been designed to evaluate whether serum concentration of PICP could be a potential marker of collagen deposition in the atria of patients with AF.
Methods: Twenty-four patients (11 with AF and 13 controls) were included, and a tisular sample of left atria was obtained, to quantify the area of myocardium occupied by collagen (CVF) by image analysis, as well as a blood sample, to measure circulating levels of PICP by ELISA.
Results: CVF was increased (P<0.005) in the left atria of patients with AF compared to control subjects. Most of the collagen deposited in the left atria was interstitial collagen, being different between two groups of patients (P<0.005). On the other hand there were no statistical differences in perivascular collagen deposition between the two groups. Serum levels of PICP were increased (P<0.01) in the group of patients with AF compared to the control group. Finally, a direct and significant association (r=0.578, P<0.05) was observed between blood levels of PICP and CVF evaluated in the left atria in all patients includes in the study.
Conclusion: These results suggest that an increase in atrial fibrosis takes places in patients with AF, and that serum PICP could be used as a biochemical marker of this structural alteration in this pathology.
- © 2010 by American Heart Association, Inc.